Fasted Morning Runs, Hypoglycemia, and New Neuropathy in a Runner With Type 2 Diabetes

Three findings change the plan before training volume is discussed.

1. Symptomatic glucose of 58–62 mg/dL after runs. These readings are below the typical 70 mg/dL threshold and came with confusion and sweating, which is clinically meaningful, not a minor nuisance. Metformin alone rarely causes hypoglycemia, but fasted endurance work, low carbohydrate availability, and possible medication timing interactions make the pattern worth a physician review. I need individualized glucose targets, a written fueling plan, and instructions on when to check glucose around exercise.
2. Bilateral foot numbness for three months. New or progressive peripheral neuropathy needs medical evaluation. Reduced foot sensation affects pacing, footwear, blister and ulcer risk, and balance. I would not simply tell her to "run more" until this is assessed.
3. Unclear exercise parameters from the clearing physician. "Cleared for exercise" is not the same as cleared for half-marathon volume with fasting. I would request specific glucose ranges, symptoms that should stop exercise, and whether her medication timing should change on long-run days.

My reasoning is scope: I can program running and general nutrition education, but I cannot diagnose neuropathy, set glycemic targets, or manage medication. The safe sequence is medical clarification, then a conservative progression while she learns to fuel and monitor.

I would validate the goal but challenge the strategy with the evidence she is missing.

• Fasted running is not required for fat loss. Fat oxidation during a session does not determine 24-hour energy balance. Weight loss comes from a sustained deficit she can tolerate, not from making training harder.
• Her own data already show the risk. Two symptomatic episodes at 58–62 mg/dL after fasted 70-minute runs are a strong argument against repeating the experiment, especially as long runs extend to 90–120 minutes.
• Carbohydrate availability affects performance and safety. For endurance work, low pre-run fuel can reduce pace stability, increase perceived effort, and raise the chance of another hypoglycemic episode. I would discuss a small pre-run carbohydrate dose, such as 15–30 g, and a trial-and-error fueling schedule built with her physician or a registered dietitian.
• Cutting carbohydrates aggressively while increasing mileage is a poor combination. It risks underfueling, poor recovery, and rebound eating. A modest deficit with adequate protein and carbohydrate around key sessions is more defensible.

I would not prescribe a exact macro plan. I would refer to a registered dietitian for medical nutrition therapy and frame my role as helping her test fueling during runs, log symptoms, and adjust training load.

I would periodize the plan around duration rather than around a fixed weekly mileage number.

Weeks 1–4 (build tolerance): Keep most runs easy and short enough that she can finish without symptoms. Have her test a small carbohydrate dose before runs longer than 45 minutes, carry fast carbohydrate, and log glucose before, during if symptomatic, and after. No fasted runs longer than 30 minutes until the physician and dietitian agree. Increase long-run duration gradually and keep one rest day after the longest run.

Weeks 5–10 (race-specific volume): Extend the long run and practice race fueling at the durations she will use. Add a mid-run carbohydrate trial on longer days. Monitor foot sensation, foot skin, and any dizziness or confusion. If glucose drops below the agreed threshold or symptoms recur, stop and revise with the medical team rather than pushing through.

Weeks 11–14 (taper): Reduce volume while maintaining some intensity and rehearsal of race-day timing. Confirm medication timing and breakfast on race morning with her physician and dietitian.

The reasoning is that fueling should be rehearsed like any other training variable, and progression should be driven by symptom-free tolerance, not by a calendar alone.